Skip to main content
Quest Diagnostics

Results of Multi-Gene Panel Testing, Including PKD1, in >1,200 Patients With Cystic Kidney Disease: A Retrospective Analysis

Results of Multi-Gene Panel Testing, Including PKD1, in >1,200 Patients With Cystic Kidney Disease: A Retrospective Analysis

Authors: Tapper EE, Huusko JM, Scocchia AM, Gall K, Roberts M, Bernal-Quirós M, Valo S, Saarinen I, Rantanen M, Pietila T, Gentile M, Koskinen L, Kumar MM, Myllykangas S, Koskenvuo J

Citation: Kidney Medi. 2025 Nov 13. doi: 10.1016/j.xkme.2025.101186. Online ahead of print.

Specialties: Genetics, Nephrology

Disclaimer: One or more of the authors of this publication were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

 

 

Related content

Conference Presentation
Case Examples of Classifying Copy Number Variants
Audio Podcast
Instant Insight: Kidney Profile and Cystatin C
Publication
Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.